E. Jager(1), V. H.J. van der Velden(2), J. G. te Marvelde(2), R. B. Walter(3,4), Z. Agur(1,6), V. Vainstein(1,5). Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based pharmacokinetic model for treatment strategy improvement and prediction of individual responses.
|
Venkata Pavan Kumar Vajjah, Stephen B Duffull Novel graphical diagnostics for assessing fit of logistic regression models
|
Antic J. (1,2), Chenel M. (2), Laffont C. M. (1), Concordet D. (1). Nonparametric Methods: When to use them? Which method to choose?
|
Elena Soto(1), Alexander Staab(2), Gerd Munzert(2), Holger Fritsch(2), and Iñaki F. Trocóniz(1) Prediction of haematological effects of a new combination of anticancer drugs, BI 2536 (a PLK1 inhibitor) and pemetrexed, using a semi-mechanistic population model for neutropenia
|
Matthew M. Hutmacher(1) and Jonathan L. French(2) Estimating Transformations for Population Models of Continuous, Closed Interval Data
|
Bertrand J (1), Comets E (1), Laffont CM (2), Chenel M (3), Mentré F (1) Model-based tests to detect gene effect in pharmacokinetic studies
|
Ron J Keizer (1), Anubha Gupta (2), Mendel Jansen (2), Jantien Wanders (2), Jos H Beijnen (1,4), Jan HM Schellens (3), Mats O Karlsson (5), Alwin DR Huitema (1) Modeling of hypertension in response to anti-angiogenic therapy
|
Joakim Nyberg, Mats O. Karlsson, Andrew C. Hooker Population optimal experimental design for discrete type data
|
Amzal B., Dorne J.-L. Population TK/TD for chemical risk assessment and drug safety: the cadmium example
|
Diane D. Wang, Shuzhong Zhang Standardized Visual Predictive Check – How and When to used it in Model Evaluation
|
WS Denney (1), Y Hang (2), MF Dockendorf (1), C-C Li (1), SR Eid (3), R Valesky (1), T Laethem (5), P Van Hoydonck (5), I DeLepeleire (5), JNJM de Hoon (6), M Crutchlow (4), R Blanchard (4) Modeling and Simulation for Determination of the Therapeutic Window of MK-2295: a TRPV1 Antagonist
|
Robert J. Bauer and Thomas M. Ludden Improvements and New Estimation Methods in NONMEM 7 for PK/PD Population Analysis
|
David Ternant (1,2), Emilie Hénin (1), Guillaume Cartron (3), Michel Tod (1), Gilles Paintaud (1), Pascal Girard (1) Model-based optimization of rituximab dosing regimen in follicular non-Hogdkin lymphoma
|
N. Hayashi (1), L. Harnisch (2) Population PK of Sildenafil and PK/PD assessment of Exercise tolerability in children with Pulmonary Arterial Hypertension (PAH)
|
Marc Lavielle (1) and Radojka M. Savic (2) A new SAEM algorithm for ordered-categorical and count data models: implementation and evaluation
|
B. Ribba, E. Watkin, M. Tod, P. Girard, B. You, B. Tranchand, E. Grenier, G. Freyer Estimating the kinetic parameters of vascular tumor growth models to optimize anti-angiogenesis drugs delivery
|
Andreas Kuttler, Thomas Dimke, Steven Kern, Gabriel Helmlinger, Luca A. Finelli A 3D Computational Model Of Cerebrospinal Fluid Dynamics For Predictive Biosimulation
|
W.H.O. Clausen (1), B.B.Rønn (1) I.M.Skovgaard (2) Maximum likelihood estimation in nonlinear mixed effect models: Adaptive Gaussian Quadrature by sparse grid sampling
|
C. Hu(1), H. Zhou(1) Confirmatory Phase III Population Pharmacokinetic Analysis
|
F.Stringer (1), B.Ploeger (2,3), J. de Jongh (2,3), G.Scott (1), R Urquart (5), A.Karim (4) and M. Danhof (2,3) Genotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar
|
Nick Holford (1), Rory Leisegang (2), Gary Maartens (2) The Influence of the Time Course of CD4 and Viral Load on Clinical Outcome Events Before and During Antiretroviral Therapy
|
Laffont C. M., Concordet D. A new exact test to globally assess a population PK and/or PD model
|
Michael Looby, Guenther Kaiser, Beatrice Abrams and Bill Sallas Elucidation of the optimal dosing scheme of an antiviral drug in children
|
N. Gobeau, B. Boulanger, L.Sargentini-Maier Comparison of different tools for the optimization of a pediatric clinical trial
|
W. de Winter(1), S. Rossenu (1), A. Dunne (1), A. Vermeulen (1) Integrating a Model for Weight Change into the Mechanism-Based Model for Type 2 Diabetes
|
Andrew C. Hooker (1), Gomeni R (2), Stefano Zamuner (2) Time to Event modeling of dropout event in clinical trials
|
Willem de Winter Issues of size and scaling in comparative biology
|
Brian Anderson Are Children Small Adults?
|
Robert M. Kalicki, Rocío Lledó-García, Mats O. Karlsson Modeling of Red Blood Cell (RBC) Lifespan (LS) in a Hematologically Normal Population
|
Catherijne Knibbe Are Children Small Adults: What can modeling offer to (clinical) practice?
|